Novartis
NVS
Market cap $239B

121.02 USD

-2.71

2.19%

At close Jul 11, 4:00 PM EDT

1 day

-2.19%

5 days

-0.99%

1 month

2.50%

3 months

12.56%

6 months

21.91%

Year to date

24.58%

1 year

9.52%

5 years

40.59%

10 years

29.72%

About: Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Employees: 75,883

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,312 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

56% more funds holding in top 10

Funds holding in top 10: 9 [Q4 2024] → 14 (+5) [Q1 2025]

52% more first-time investments, than exits

New positions opened: 120 | Existing positions closed: 79

19% more capital invested

Capital invested by funds: $12.9B [Q4 2024] → $15.4B (+$2.44B) [Q1 2025]

0.63% more ownership

Funds ownership: 5.95% [Q4 2024] → 6.58% (+0.63%) [Q1 2025]

1% more funds holding

Funds holding: 1,321 [Q4 2024] → 1,328 (+7) [Q1 2025]

12% less call options, than puts

Call options by funds: $246M | Put options by funds: $281M

16% less repeat investments, than reductions

Existing positions increased: 421 | Existing positions reduced: 500

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for NVS.

See Analyst Rankings

Financial journalist opinion

Based on 23 articles about NVS published over the past 30 days

Novartis loses bid to block US Entresto generic through 2026

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto through late 2026, a Delaware federal judge said on Friday.

Novartis loses bid to block US Entresto generic through 2026

Zacks Investment Research

Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump

Trump revives tariff threats on pharma imports, but industry giants like LLY and JNJ stay unfazed with major U.S. investments underway.

Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump

Zacks Investment Research

Why Novartis (NVS) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Novartis (NVS) is a Top Value Stock for the Long-Term

Novartis gets approval for first malaria drug for babies and children

Novartis on Tuesday said it had received approval in Switzerland for Coartem, which it said was the first drug to treat malaria in babies and young children.

Novartis gets approval for first malaria drug for babies and children

Novartis receives approval for first malaria medicine for newborn babies and young infants

Basel, July 8, 2025 – Novartis today announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet® Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.

Novartis receives approval for first malaria medicine for newborn babies and young infants

Zacks Investment Research

Here's Why Novartis (NVS) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Novartis (NVS) is a Strong Momentum Stock

Zacks Investment Research

Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study

NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.

Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study

Novartis drug Cosentyx fails late-stage trial for artery disease

Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition characterised by inflammation of the arteries.

Novartis drug Cosentyx fails late-stage trial for artery disease

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile of Cosentyx® (secukinumab)1 EAST HANOVER, N.J. , July 3, 2025 /PRNewswire/ -- Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

See News Rankings

Charts implemented using Lightweight Charts™